Investors can sue Novo Nordisk over 2024 stock losses

Investors have been granted the right to sue Novo Nordisk over stock losses suffered in 2024, following a significant drop in the company's share price after disappointing clinical trial results. A judge in New Jersey made the decision on Wednesday, allowing the case to move forward.

The lawsuit was initially filed in January 2025 against the pharmaceutical giant, its research director Martin Holst Lange, and former CEO Lars Fruergaard Jørgensen. Novo Nordisk had attempted to have the case dismissed, but this effort was unsuccessful.

At the heart of the legal action is the question of whether Novo Nordisk misled investors regarding its weight-loss medication, Cagrisema. Specifically, the case alleges that the company allowed investors to believe the drug would achieve greater weight loss than the final trial results indicated. In 2024, the company announced trial results showing a 22.7% weight loss, which was notably lower than the 25% anticipated by investors.

The discrepancy between management's prior communications, which suggested an expected 25% weight loss, and the actual trial outcome led to a significant market reaction. Novo Nordisk's stock price fell by over 20% immediately after the trial results were published, prompting the investor lawsuit.